Raj Puri Email

EVP, Regulatory Strategy and Translational Medicine . Iovance Biotherapeutics

Current Roles

Employees:
550
Revenue:
$13.8M
About
Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively. Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. In addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.
Iovance Biotherapeutics Address
999 Skyway Road
San Carlos, CA
United States
Iovance Biotherapeutics Email
Iovance Biotherapeutics Phone Numbers
650-260-7120

Past Companies

Iovance Biotherapeutics, Inc.Executive Vice President, Regulatory Strategy and Translational Medicine
FDA, Center for Biologics Evaluation and ResearchDivision Director
Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, FDA, CBERBranch Chief

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.